One of the clinically most relevant breast cancer subtypes are ER+ tumors, which comprise around 70% of diagnosed cases (Fillmore et al., 2010) and generally have a better prognosis than ER− tumors (Bae et al., 2015). The gene discussed is ESR1; the disease is breast carcinoma.